Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3

INTRODUCTION: In pivotal phase 3 tralokinumab monotherapy (ECZTRA 1/2) and topical corticosteroid (TCS) combination (ECZTRA 3) trials in adults with moderate-to-severe atopic dermatitis (AD), tralokinumab significantly improved signs and symptoms of AD. Geographic region may impact treatment respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Gooderham, Melinda, Bhatia, Neal, Langley, Richard G., Schneider, Shannon, Zoidis, John, Kurbasic, Azra, Armstrong, April, Silverberg, Jonathan I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588100/
https://www.ncbi.nlm.nih.gov/pubmed/36152216
http://dx.doi.org/10.1007/s13555-022-00805-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588100/
https://www.ncbi.nlm.nih.gov/pubmed/36152216
http://dx.doi.org/10.1007/s13555-022-00805-y

Ejemplares similares